NBI’s product portfolio consists of 13 therapeutic protein products of human origin, which are administered intravenously or intramuscularly. NBI’s products can only be obtained with a doctor’s prescription. Patients are advised to discuss with their doctor the reason for prescribing the medication and the benefits and risks of the medicine. All NBI’s products are registered with the South African Health Products Regulatory Authority (SAHPRA). NBI transforms plasma into life-saving therapies, using the process of cold ethanol fractionation. Click here for more..

NBI’s human plasma product is used in cases where plasma and/or clotting factors are needed.

NBI’s human normal immunoglobulins are available as intramuscular injections or intravenous infusions.
The intramuscular normal immunoglobulin can be used for patients who need replacement of some antibodies or to prevent infection by the hepatitis A virus.
The intravenous normal immunoglobulin is used to replace antibodies which are missing in primary and secondary antibody deficiency syndromes. It is also used in the treatment of auto-immune diseases such as Kawasaki Disease, Guillain Barré Syndrome, Primary Immune Thrombocytopenia (also known as Idiopathic Thrombocytopenic Purpura) and as an immunoglobulin supplement during bone marrow transplantation.

Human albumin solutions are recommended for use in the management of low blood volume, extensive burns, low protein levels, ascites, and in patients undergoing dialysis or plasma exchange.

Human anti-D immunoglobulin can be administered to a rhesus-negative patient who may be exposed to blood that is rhesus-incompatible with their own. Examples of this would be during pregnancy or blood transfusions.
Human hepatitis B immunoglobulin contains antibodies to the hepatitis B virus and can prevent a hepatitis B infection from developing in a person who has been exposed to this virus, including babies born to mothers with a hepatitis B infection.
Human rabies Immunoglobulin is indicated for all persons known or suspected to have been exposed to the rabies virus.
Human tetanus immunoglobulin is used for the prevention of tetanus in a person who has not been recently immunised and who has suffered an injury that could put them at risk of exposure to the tetanus bacteria. It is also used for the treatment of clinical tetanus to bind any unbound neurotoxin.
Human varicella-zoster immunoglobulin is used to prevent chickenpox in patients who have been exposed to the varicella-zoster virus and who are at risk of severe complications of chickenpox.

NBI's human factor VIII concentrate contains coagulation factor VIII and von Willebrand factor and is used to treat haemophilia A and von Willebrand disease with factor VIII deficiency.

NBI's human factor IX complex contains coagulation factors II, VII, IX and X and is used for the treatment of haemophilia B or bleeding resulting from an overdose of warfarin (a medicine that prevents blood clots from forming).